Atypical food intake is a primary cause of obesity and other eating and metabolic disorders. Insight into the neural control of feeding has previously focused mainly on signalling mechanisms associated with the hypothalamus 1-5 , the major centre in the brain that regulates body weight homeostasis 6, 7 . However, roles of non-canonical central nervous system signalling mechanisms in regulating feeding behaviour have been largely uncharacterized. Acetylcholine has long been proposed to influence feeding [8] [9] [10] owing in part to the functional similarity between acetylcholine and nicotine, a known appetite suppressant. Nicotine is an exogenous agonist for acetylcholine receptors, suggesting that endogenous cholinergic signalling may play a part in normal physiological regulation of feeding. However, it remains unclear how cholinergic neurons in the brain regulate food intake. Here we report that cholinergic neurons of the mouse basal forebrain potently influence food intake and body weight. Impairment of cholinergic signalling increases food intake and results in severe obesity, whereas enhanced cholinergic signalling decreases food consumption. We found that cholinergic circuits modulate appetite suppression on downstream targets in the hypothalamus. Together our data reveal the cholinergic basal forebrain as a major modulatory centre underlying feeding behaviour.
. Given this correlation, we sought to determine if cholinergic neurons in the mouse DBB modulate feeding. With feeding after an overnight fast, we observed co-localization between c-Fos and the cholinergic-specific marker, choline acetyltransferase (ChAT) (Fig. 1a-f ). Given their activation in response to food intake, we next assessed the necessity of cholinergic DBB neurons in feeding modulation. We stereotaxically targeted cholinergic DBB neurons for ablation using a Cre-dependent 14 adeno-associated virus (AAV) that expressed an enhanced yellow fluorescent protein (EYFP)-linked diphtheria toxin receptor in Chat-cre
LSL-tdTomato/+ mice. DBB cholinergic neurons were mainly decimated after treatment with diphtheria toxin, whereas those in surrounding areas of the brain were unaffected (Fig. 1g-n) . Within two weeks after ablation, we observed hyperphagia ( Fig. 1o ) and severe obesity ( Fig. 1p-q) . To assess the extent that food consumption contributed to this phenotype, we conducted paired feeding assays on obese DBB-ablated animals versus their non-ablated controls. Control mice exhibited normal food intake and minimal weight gain, whereas DBB-ablated animals lost weight when available food was limited to control levels ( Fig. 1r-s) , suggesting that hyperphagia was required to maintain obesity. This effect did not appear to be mediated by changes in energy expenditure, as overall levels of activity ( Fig. 1t ) and oxygen consumption (Extended Data Fig. 2a ) were unaffected during early stages post-DBB ablation. Metabolic activity was only altered once obesity became a burden (Extended Data Fig. 2b-k) .
We sought to determine whether conditional removal of cholinergic neurotransmission selectively from the DBB, without cell death, led to increased food consumption and obesity. We stereotaxically delivered an EGFP-Cre-expressing AAV into the DBB of Chat loxP/loxP homozygous mice (Fig. 2a) , and evaluated ChAT knockout by immunohistochemistry ( Fig. 2b-k) . Counts of ChAT-immunopositive neurons from control and experimental brains showed a 72% and 55% decrease in ChAT expression in the DBB of Cre-expressing female and male mice, respectively, compared to controls (Fig. 2l ). Consistent with a role for cholinergic signalling in feeding behaviour, Cre-expressing animals displayed increased food intake ( Fig. 2m ) and subsequent weight gain (Fig. 2n) . Because knockout is restricted to the Chat gene, these data imply that the observed effects on feeding and body weight were mediated by cholinergic signalling, although it does not rule out a role for GABAergic neurotransmission from cholinergic DBB neurons, which have recently been reported to co-release GABA 15 (Extended Data Fig. 3a-c) .
To test how acute inactivation of these neurons affected food intake, Chat-cre +/− mice were DBB-targeted for conditional expression of hM4D-EGFP (Extended Data Fig. 4a ). Following CNO treatment, hM4D-EGFP-expressing mice consumed more food compared to controls (Extended Data Fig. 4b ), suggesting that both acute and chronic inactivation of cholinergic DBB neurons were sufficient to increase food intake.
We sought to determine if activating DBB cholinergic neurons was sufficient to suppress food intake in vivo. To test this, we expressed channelrhodopsin-2 (ChR2) in DBB cholinergic neurons, followed by monitoring feeding behaviour during photostimulation ( Fig. 3a-g ). We found that prolonged (48 h) activation of cholinergic DBB neurons significantly decreased daily food intake under conditions of normal food access (Fig. 3h, i) , whereas mock-stimulated, non-ChR2-expressing controls showed no significant changes in feeding behaviour (average daily food intake was 4.26 g (±0.22 g, s.e.m.); 112.48% of baseline (±5.91%, s.e.m.), n = 3). To test the acute effect of DBB stimulation on feeding, we fasted ChR2-expressing mice overnight and presented them with chow in the morning. We observed that acute cell body stimulation resulted in a similar overall decrease (approximately 25%) in food intake ( Fig. 3j-k) .
We selectively targeted cholinergic DBB neurons for conditional viral expression of a presynaptically localized, synaptophysin-EGFP (Extended Data Fig. 5a-e) , allowing the identification of their presumptive downstream synaptic targets. Using this method, we observed DBB neuron terminals in previously reported areas of the brain 11 (Extended Data Fig. 5f -n), as well as in ventral-medial domains of the hypothalamus (Extended Data Fig. 5o-u) , which have previously been shown to express markers for cholinergic Letter reSeArCH terminals of unknown origin 16 . Within this region resides the arcuate nucleus of the hypothalamus, a site that contains well-characterized cell populations that conversely regulate hunger and satiety through NPY/AgRP-expressing and POMC-expressing neurons, respectively 17 . As cholinergic basal forebrain neurons co-express GABA, it is possible that loss of cholinergic neurons from the DBB could disinhibit AgRP neurons, thereby promoting food intake through elevated expression levels of Agrp. To test this, Agrp transcripts were assessed in DBBablated animals that were pair-fed to respective controls shortly after ablation, before hyperphagic-induced obesity. Under these conditions, Agrp transcript analysis from the arcuate nucleus of DBB-ablated animals showed no significant decrease in levels of Agrp compared to controls (Extended Data Fig. 6a) . Interestingly, however, Pomc transcript levels were strikingly reduced in DBB-ablated mice (Extended Data Fig. 6a ), suggesting that cholinergic DBB neurons may normally act to modulate downstream satiety pathways. Previous reports show that POMC neurons are activated by cholinergic nicotinic agonists, however, their effect on AgRP/NPY neurons appears much more variable. From our own recordings (Extended Data Fig. 6b ), acetylcholine did not show fast excitation on NPY neurons, perhaps due to muscarinic acetylcholine receptor (mAChR) activity or through broader network effects.
Recent studies have implicated the arcuate nucleus in appetite suppression via AChR signalling onto POMC neurons 18 , and conditional rabies virus tracing experiments suggested that arcuate POMC neurons receive significant input from neurons in the DBB 12 . Whole-cell g-n, DBB of saline-treated (g-j) or diphtheria toxin treated (k-n) animals. Scale bars, 100 μ m. o, Food intake between DBB-ablated (n = 15 mice) and non-ablated animals (n = 13 mice). Time points represented as mean ± s.e.m., P = 0.0002, F (1, 26) = 18.06 by two-way ANOVA with repeated measures. p, Body weight between DBB-ablated (n = 15) and non-ablated animals (n = 13). Time points represented as mean ± s.e.m., P < 0.0001, F (1, 26) = 143.1 by two-way ANOVA with repeated measures. q, Representative DBB-ablated and non-ablated mice. r, s, Average daily food intake (r) and body mass (normalized with respect to the day-0 mass; s) during paired feeding (n = 5 mice per group), pink shading represents restrictive period. t, Total time active per day before obesity, and during early and late stages of obesity. Data represented as mean ± s.e.m., * P < 0.05 by two-sided, unpaired Student's t-test. Data represented as mean ± s.e.m., * P < 0.05, * * P < 0.01 by two-sided, unpaired Student's t-test. m, n, Daily average food intake (m) and average body mass (n) (12 weeks after the conditional knockout, n = 7 females, 5 males for EGFP-Cre or EGFP mice, n = 6 females, 6 males for wild type). Data represented as mean ± s.e.m., * P < 0.05, * * P < 0.01 by two-sided, unpaired Student's t-test. Schematic in a was adapted from an image from the Allen Brain Institute Reference Atlas 30 . Letter reSeArCH recordings from labelled POMC neurons in Pomc-EGFP +/− mice showed that neuronal firing increased in the presence of acetylcholine (Extended Data Fig. 6c-d) , and this response was blocked by AChR blockers (Extended Data Fig. 6e ). To assess potential connectivity between the DBB and arcuate nucleus, we implemented retrogradely transported canine adenovirus (CAV-2) 19 . Using conditional R26 LSL-tdTomato/+ mice, we delivered CAV-Cre into the arcuate nucleus, and found that cholinergic DBB neurons provide input (Fig. 4a-e) . Non-cholinergic cell types in the DBB were also labelled, suggesting that both cholinergic and non-cholinergic cell types from the DBB provide input into the hypothalamus to regulate its functions. To investigate this connectivity in vivo, Chat-cre +/− mice were targeted for conditional ChR2::EYFP expression in DBB cholinergic neurons, and a fibre optic was implanted into the ventral space of the third ventricle to stimulate DBB terminals within the ventral hypothalamus (Fig. 4f ). ChR2-expressing and non-ChR2-expressing (mock-stimulated) implanted animals were fasted overnight and presented with chow for two hours. Mock-stimulated animals showed no significant changes in feeding behaviour during photostimulation (average was 1.381 g (± 0.1429 g, s.e.m.); 117.1% of baseline (±12.12%, s.e.m.), n = 6 animals), whereas stimulated ChR2-expressing animals exhibited diminished food intake compared to non-stimulated conditions ( Fig. 4g-h ), consistent with decreases observed from DBB cell body stimulation, and supporting anatomical tracing data. Although these data support a role for cholinergic modulation of the arcuate nucleus, given sparse labelling of terminals throughout the hypothalamus, as well as dense innervation of the median eminence (Extended Data Fig. 7a-h ), these results do not rule out an influence of other hypothalamic sites and cell types. Lastly, to test if this effect was AChR-mediated, we systemically injected showing ChAT and tdTomato co-localization. f, Strategy for ChR2-assisted in vivo behaviour. g, h, Total (g) and normalized (with respect to the mean no-stimulation value; h) food intake (n = 8 mice) after two-hour re-feeding after overnight fast. Data represented as mean ± s.e.m. * P = < 0.05 by two-sided, paired Student's t-test. Schematics in figures a and f were adapted from images from the Allen Brain Institute Reference Atlas 30 .
Figure 3 | In vivo
ChR2-mediated DBB stimulation decreases food intake. a, ChR2::EYFP in cell bodies of the DBB. Scale bar, 1 mm. Membrane-bound ChR2::EYFP is not restricted to cell bodies and shows neuronal projections. b-d, ChR2::EYFP in DBB neurons after stimulation and stained to identify c-Fos. e, f, Strategy for ChR2-assissted feeding assay. g, Representative recordings from a ChR2-expressing cholinergic DBB neuron (10 ms pulses, 20 Hz, 5 s trains, 30 s intervals). h, i, Raw (h) and normalized (with respect to the mean pre-stimulation value; i) food intake values before, during, and post-stimulation (n = 7 mice). j, k, Raw (j) and normalized (with respect to the mean no-stimulation value; k) food intake values in the absence or presence of stimulation (n = 5 mice). Data represented as mean ± s.e.m., * P < 0.05 by two-sided, paired Student's t-test. Schematic in e was adapted from an image from the Allen Brain Institute Reference Atlas 30 . Letter reSeArCH photostimulated animals with the nicotinic cholinergic receptor (nAChR) antagonist mecamylamine, which has previously been shown to block nAChR-mediated decreases in food intake 18 . In the presence of mecamylamine, photostimulated animals showed a blunted response compared to stimulation alone (Extended Data Fig. 8a-b) , suggesting that decreased food intake after stimulation was mediated in part by AChR signalling. Notably, however, we did not observe a complete phenotypic blockade, suggesting that mAChR signalling may play a synergistic role in modulating food intake, and may therefore explain why nAChR antagonism alone was not sufficient to fully suppress feeding.
AAV-FLEX-ChR2::EYFP
Together, our data demonstrate a powerful role for cholinergic basal forebrain neurons in modulating food intake. Cholinergic systems are highly druggable, which may offer a new avenue for targeting cholinergic mechanisms to help treat eating disorders. AChR transcript analysis from the arcuate nucleus showed expression of common AChR subunits (Extended Data Fig. 9a ), serving as possible targets for pharmacological interventions. Understanding the AChR profiles of prominent feeding-associated cell types will surely be useful in this respect 20 . Additionally, revealing the contribution of other signalling mechanisms from cholinergic neurons will be essential in understanding their composite roles in feeding. Cholinergic and other neuromodulatory systems are known to co-express multiple neurotransmitters and/or neuropeptides 15, 21, 22 . Although cholinergic signalling is sure to play an important role, it remains unclear how dual transmitter systems function in concert to modulate their targets. Although our studies indicate a modulatory effect of acetylcholine on POMC neurons to influence food intake, it is possible that other cell types of the hypothalamus and/or other brain regions may be affected in a manner yet to be determined by cholinergic innervation. As such, it is possible that our observed phenotypes are not due solely to downstream effects in the arcuate nucleus alone, but may be a combinatorial effect of altered cholinergic signalling at other projection sites or cell types of the hypothalamus or other innervated brain regions. It will be especially interesting to determine the role of alternative cholinergic centres in modulating feeding behaviour such as those associated with the reward and addiction pathways of the mesolimbic system. The boundary between homeostatic and non-homeostatic (hedonic/aversive) control of feeding is not always distinct or clear-cut, and often converges 23, 24 . Given its role as a powerful modulator of reward [25] [26] [27] [28] and aversion 26, 27, 29 , and its involvement in addiction 26, 27 , acetylcholine is a prime candidate that may link known canonical homeostatic mechanisms that govern feeding behaviour, with the reward and/or aversive aspects of food intake. Nonetheless, fully understanding the relationship between cholinergic systems and their role in modulating feeding behaviour is an important step towards uncovering a comprehensive profile of feeding regulation.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. , Pomc-EGFP, and Npy-hrGFP animals was done according to available Jackson Laboratory protocols for these strains. Genotyping for Cre was done using primers for Cre recombinase detection (forward primer: 5′ -GCATTTCTGGGGATTGCTTA-3′ , reverse primer: 5′ -GTCATCCTTAGCGCCGTAAA-3′ ). Microscopy and immunohistochemistry. Animals were deeply anaesthetized using isoflurane and were transcardially perfused with PBS followed by 10% neutral buffered formalin (NBF, Azer Scientific). Brains were dissected and post-fixed in 10% NBF overnight at 4 °C. Brains were cryoprotected in a 20% sucrose/PBS solution at 4 °C for one day, followed by a 30% sucrose/PBS solution at 4 °C for one more day. Brains were then embedded and frozen in OCT and stored at − 80 °C. Brains visualized using endogenous or virally-expressing fluorescent reporters were cut using a cryostat (Leica CM1860) in coronal sections at 25-30 μ m. For ChAT and β -endorphin immunohistochemistry, 40 μ m free-floating sections were blocked for 1 h at room temperature in 10% horse serum blocking solution, made in PBS-TC (1× PBS, 0.5% Triton-X 100, 0.1 mM CaCl 2 , pH 7.35). Sections were then incubated overnight at 4 °C at a 1:200 dilution of block solution containing goat anti-ChAT primary antibody (Millipore, AB144P) or rabbit anti-β -endorphin primary antibody (Phoenix Pharmaceuticals, H-022-33). Sections were then washed 4 times, 30 min each in plain PBS-TC. Sections were then incubated in secondary antibody (donkey anti-goat Alexafluor-488 or Alexafluor-555, Life Technologies) at a 1:200 dilution for 3 h at room temperature. Sections were then washed 4 times for 30 min each in PBS-TC. All sections were mounted using DAPI Fluoromount-G (Southern Biotech, 0100-20). Detection of fluorescent expression was performed using a Leica TCS SPE confocal microscope under a 10× or 20× objective. Stereotaxic injections and viral constructs. For all stereotaxic injections, mice were anesthetized using a ketamine/dormitore mixture and were maintained under anaesthesia using vaporized isoflurane with O 2 . All injections were performed using a stereotaxic apparatus synced to Angle Two software for coordinate guidance. For DTR-mediated cell death of cholinergic neurons, female Chat-cre
LSLtdTomato/+ mice (8-10 weeks old) were bilaterally injected into the horizontal limb of the diagonal band of Broca (HDB, right hemisphere, from bregma: AP = + 0.14, DV = − 5.80, ML = − 1.29; left hemisphere, from bregma: AP = + 0.14, DV = −5.74, ML = + Neuronal activation after feeding and c-Fos IHC. Male wild-type animals were fasted overnight before being presented with standard pellet mouse chow (Harlan, 2920X) for 3 h the following morning (fed group), while a second group of mice was fasted overnight but not presented with chow (fasted group). Mice were then immediately euthanized and perfused with PBS and 10% NBF. Brains were fixed overnight in 10% NBF before two overnight fixations in 20% and 30% sucrose/PBS solutions. Brains were frozen in OCT cutting compound and cryosectioned at 35 μ m. Sections were then blocked for 1 h at room temperature in 10% horse serum blocking solution, made in PBS-TC (1× PBS, 0.5% Triton-X 100, 0.1 mM CaCl 2 , pH 7.35). Sections were then incubated overnight at 4 °C at a 1:200 dilution of block solution containing goat anti-ChAT primary antibody (Millipore, AB144P) and 1:500 dilution of rabbit anti-c-Fos antibody (Calbiochem, PC38). Sections were then washed 4 times for 30 min each in plain PBS-TC. Sections were then incubated in secondary antibodies (donkey anti-goat Alexafluor-488, and donkey anti-rabbit Alexafluor-546) at a 1:200 dilution each for 3 h at room temperature. Sections were then washed 4 times for 30 min each in PBS-TC. All sections were mounted using DAPI Fluoromount-G (Southern Biotech, 0100-20). Detection of fluorescent expression was performed using a Leica TCS SPE confocal microscope under a 20× objective. DTR-mediated cell death and Chat conditional knockout assays. After allowing 10-14 days for conditional viral expression (injections and viral construct described previously), mice were intraperitoneally (i.p.) injected 3 times daily for 5 days with 800 ng (4 ng μ l For Chat conditional knockout assays, Chat loxP/loxP mice were injected bilaterally into the HDB as previously described with either AAV-EF1α-EGFP-P2A-CRE-WPRE-hGHpA for conditional knockout animals or AAV-EF1α-EGFP-WPRE-hGHpA for controls. Body weights and daily food intake were measured and averaged per group for each time point presented. For cell counts after Chat conditional knockout, 3 mice from each group were euthanized and brains were sectioned at 40 μ m for ChAT immunohistochemistry. 10 sections representing the anterior, central, and posterior areas of the DBB were chosen, and blinded, total cell counts based on ChAT immunoreactivity were tallied. A count from all 10 sections from a single mouse brain were totalled and averaged for each group of 3 mice. Data were normalized to control levels of expression and represented as a mean percentage ± s.e.m. Activity monitoring and metabolic assays. Activity (reported as time active per day), O 2 consumption, and metabolic blood assays were performed by the Baylor College of Medicine Mouse Metabolism Core before obesity phenotypes (3 days after diphtheria toxin (DT) treatment), during early stages of obesity and hyperphagia (3 weeks post-DT treatment), and at late stages of obesity and hyperphagia (3 months post-DT treatment). Activity and O 2 consumption assays were performed using the Oxymax Comprehensive Laboratory Animal Monitoring System (CLAMS, Columbus instruments). Lean mass and body fat content was assessed using quantitative MRI. Blood panel assays for cholesterol, leptin, insulin, and glucose were also performed by the Baylor College of Medicine Mouse metabolism core. Blood was collected via the tail vein. Mice were fasted for 4 h before measuring blood glucose. Paired feeding assays. Paired feeding assays were performed with individuallyhoused, male DT-treated (DBB-ablated) and saline-treated (non-ablated) animals. Assays for determining the contribution of food intake on maintaining obesity were conducted on animals 12-weeks post-ablation. First, daily body weight and ad libitum food intake for all animals was recorded for 7 days to establish baselines for all animals. Then 1 control mouse and 1 experimental mouse were then randomly paired. All food from experimental cages was removed and only an equivalent amount of food consumed the previous day by a mouse's respective control partner was introduced to the cage. This restrictive period was done for 21 days. Afterwards, all experimental mice were allowed to resume to feed ad libitum once again and food intake and body weight were measured daily for 2 weeks. Change in body weight over time was normalized as a percentage of day 1 initial starting weight for each individual animal. For paired feeding conducted on animals used for Agrp and Pomc transcript analysis, assays were performed 3 days post-ablation to prevent significant weight gain from hyperphagia. A restrictive feeding period was conducted for 21 days, after which mice were euthanized on the morning after the final day, and hypothalamic tissue was harvested for RNA purification and subsequent qRT-PCR (see below).
In vivo optogenetic behaviour assays. Concurrent with AAV-EF1α-DIOhChR2(H134R)-EYFP-WPRE-hGHpA injections (as described previously), male
Chat-cre +/− mice were bilaterally implanted with 200 μ m silica fibre optic implants made in-house (Thor Labs, TS1249968); 230 μ m ferrules (Precision Fibre Products,
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MM-FER2007C-2300) and situated 0.1 mm above the viral injection site. Fibre optic implants were held in place by a cap made from adhesive cement (C&B Metabond Quick! Cement System (Parkell)) for initial base, and crosslinked flash acrylic (Yates-Motloid, 44115 and 44119) for headcap. Mice were allowed at least two weeks for recovery and expression of the virus before assays were performed. For prolonged 2-day stimulation, each mouse was allowed 48 h to acclimate in a behaviour box with free access to food and water (days 1 and 2: acclimation). In addition, acclimation occurred while tethered to a dual fibre optic cord (Doric Lenses) attached to a 473 nm laser source (CrystaLaser CL-2005) . After the 48-h acclimation period, a pre-measured amount of food was placed into the chamber and weighed once every 24 h for two days without stimulation (days 3 and 4: prestimulation). Over the next 48 h, food was weighed once each day while mice were chronically stimulated with trains of blue light (5 mW, 10 ms pulses, 20 Hz, 5 s trains, 30 s intervals) (days 5 and 6: stimulation). Finally, food was weighed once every 24 h for two final days with no blue light stimulation (days 7 and 8: post-stimulation). As a control group, non-ChR2-expressing mice were injected and implanted in the identical way used for experimental mice. Control mice were acclimated identically and were subsequently subjected to a mock stimulation for 48 h, and food intake was measured each day. For comparisons between prestimulation, stimulation, and post-stimulation conditions, paired Student's t-tests were used. For comparisons between experimental conditions and the control (mock-stimulation) condition, unpaired Student's t-tests were used. For short-term 2-h stimulation experiments, mice were given 48 h to acclimate in their behaviour chamber. After acclimation, mice were fasted overnight and subsequently presented with a pre-measured amount of food in the morning. For control conditions, mice were not stimulated and food intake was recorded every 30 min for 2 h total. For experimental conditions, mice were stimulated with trains of blue light (5 mW, 10 ms pulses, 20 Hz, 5 s trains, 30 s intervals) for 15 min before presentation of pre-measured chow, and food intake was recorded every 30 min for 2 h total in presence of continued blue light illumination. Trials were randomized and conducted one week apart on the same animals. For experiments targeted at terminal stimulation in the arcuate nucleus of the hypothalamus, male animals were bilaterally injected into the HDB with AAV-EF1α-DIO-hChR2(H134R)-EYFP-WPREhGHpA, and a single fibre optic was implanted into the third ventricle at the level of the arcuate (from bregma: AP = − 1.70, DV = − 5.75, ML = 0.00). For behavioural assays, animals were first allowed 48 h to acclimate to their behaviour cage while tethered to a fibre optic cord. After acclimation, mice were fasted overnight. In the morning, mice were presented with standard pre-measured pellet chow and food intake was recorded every 30 min for 2 h total either under conditions of light stimulation (5 mW, 10 ms pulses, 20 Hz, 5 s trains, 30 s intervals) or no stimulation. Trials were randomized and conducted one week apart on the same animals. Paired statistics were used to compare 'stim' and 'no-stim' conditions on these animals. As a control group, Cre-negative male littermates were injected with virus and implanted in the same way as experimental mice. Behavioural assays on these mice were done the same way under conditions of light illumination. Comparisons between mock-stimulated and experimental cohorts were done using unpaired statistics. For terminal stimulation experiments in the presence of mecamylamine (Tocris, catalogue number 2843), mice were fasted overnight and presented with a pre-measured amount of chow in the morning. Mecamylamine was administered by i.p. injection at 1 mg per kg 15 min before the start of a 2-h feeding in the presence or absence of blue light illumination. Control (sterile 1× PBS i.p. injections) and experimental trials were conducted 1 week apart. Electrophysiology and pharmacology of POMC-EGFP or NPY-hrGFP neurons, ChR2-expressing DBB neurons, and hM4D-expressing DBB neurons. Brain slices containing the hypothalamic arcuate nucleus were prepared from 6-8-week-old Pomc-EGFP +/− or Npy-hrGFP +/− transgenic mice of either gender. For ChR2 stimulation and hM4d-mediated inhibition, brain slices containing the DBB were prepared from 12-16-week-old male animals expressing either ChR2::EYFP or hM4D-EGFP in the DBB, respectively. Animals were anaesthetized with isoflurane and brains were rapidly removed and transferred into sucrose-based cutting solution, containing (in mM): 250 sucrose, 25 NaHCO 3 , 1.25 NaH 2 PO 4 , 2.5 KCl, 1.5 MgCl 2 , 2 CaCl 2 , 10 glucose, and continuously bubbled with 5% CO 2 / 95% O 2 . 300-μ m-thick coronal brain slices were prepared using a Leica VT 1200 vibratome and placed for recovery in a 5% CO 2 / 95% O 2 bubbled regular ACSF solution, containing (in mM): 128 NaCl, 24 NaHCO 3 , 1 NaH 2 PO 4 , 3 KCl, 1 MgCl 2 , 1.6 CaCl 2 , 8 glucose. After at least 1-h recovery and 20-30 min before recording, slices were transferred into a recording chamber continuously perfused at 2 ml min −1 with aforementioned ACSF at 24 °C. POMC-, NPY-, ChR2::EYFP-, and hM4D-expressing neurons were identified by transmitted light DIC and EGFP fluorescent imaging using a Slicescope Pro 6000 optical setup (Scientifica), equipped with a CoolLED pE-100 470 nm excitation light source, 49002-ET-EGFP (FITC/Cy2) emission filter (Chroma Technology), and optiMOS camera (QImaging). Electrical activity of neurons was recorded in whole-cell current clamp mode using a Multiclamp 700b amplifier and a 1440a Digidata interface (Molecular Devices). Pipette solution contained (in mM): 10 KCl, 120 K gluconate, 1 MgCl 2 , 10 HEPES, 1 EGTA, 5 Na2-ATP, 0.01 Na-GTP, pH 7.2. To test the cholinergic effects on POMC and NPY neurons, baseline neuronal activity was prerecorded for at least 10 min to assure a stable firing rate, after which acetylcholine (Sigma-Aldrich, A6625) was added to the bath perfusion at 100 μM. For ChR2 stimulation, 12 consecutive trains of blue light were given at 30 s intervals. Each train lasted for 5 s with 10 ms light pulses delivered at 20 Hz. For recordings from hM4D-expressing cells, we recorded 90 s baseline sweeps and delivered 5 s current injections at 2 pA and 10 pA, spaced 25 s apart. This protocol was repeated again 6 min after CNO bath application. For all recordings, neuronal firing activity was analysed offline using the event detection feature of Clampfit 10.3 software (Molecular Devices). Repeated measures ANOVA with Holm-Sidak multiple comparison, and Sigma Plot 11.0 software (Systat Software) were used for statistical analyses of data, where applicable. For acute acetylcholine responses, a localized 2 s application of acetylcholine (100 mM, Sigma-Aldrich, A6625) was applied near a patched POMC-EGFP neuron (held at − 70 mV) using a FemtoJet (Eppendorf). Each recording was performed using a 20-s sweep with an inter-trial interval of 1 min and repeated for 5 sweeps each for baseline, synaptic blockers (10 μ M CNQX (Tocris), 20 μ M APV (Tocris), 50 μ M GABAzine (Tocris), and nicotinic blockers (10 μ M mecamylamine (Tocris), 0.1 μ M methyllycaconitine citrate (Tocris), and 10 μ M dihydro-β -erythroidine hydrobromide (Tocris).
CAV-Cre tracing experiments. R26
LSL-tdTomato animals were stereotaxically injected bilaterally with 70 nl of CAV-Cre virus (purchased from the vector core at the Institut de Génétique Moléculaire de Montpellier) targeted to the arcuate nucleus (from bregma: AP = − 1.70, DV = − 5.80, ML = ±0.20). Sections through the DBB were obtained and stained for ChAT using the identical ChAT IHC protocol detailed previously. All sections were mounted using DAPI Fluoromount-G (Southern Biotech, 0100-20). Detection of fluorescent expression was performed using a Leica TCS SPE confocal microscope under a 10× or 20× objective. hM4D-mediated feeding assays. 12-week-old, male Chat-cre +/− mice were sterotaxically injected bilaterally into the DBB (500 nl per hemisphere) with an hM4D-EGFP-expressing AAV (AAV-CBA-FLEX-hM4Di-P2A-EGFP-WPRE-sv40pA, serotype 2/9, Addgene, plasmid number 52536). After a two-week recovery, mice were fasted overnight in their home cage, and food was presented in the morning. Food intake was measured every 30 min for 2 h total, in the presence or absence of CNO. For control experiments, mice were injected i.p. with sterile saline and allowed to wait 15 min before food presentation. For experimental conditions, mice were injected i.p. with CNO (5 mg per kg) and allowed to wait 15 min before food presentation and measurement, which was recorded for 2 h in total. Trials were randomized and conducted one week apart on the same animals. Paired statistics were used to compare 'saline' and 'CNO' conditions on these animals. Transcript analyses. For Agrp and Pomc transcript analysis from the arcuate nucleus, 4 DBB-ablated mice and 4 non-ablated mice were euthanized in the morning and their brains were immediately dissected. For AChR transcript analysis, 4 wild-type male mice were taken and brains dissected and processed identically. Small sections of the ventral hypothalamus containing the arcuate nucleus were dissected out and RNA was isolated following the TRIzol (Life Technologies, 15596-018) protocol for tissue homogenization and RNA isolation. In brief, tissue was placed in 1 ml of TRIzol reagent and homogenized using a 1.5 ml pre-sterilized pestle. Homogenized samples were allowed to incubate at room temperature for 5 min. 0.2 ml of chloroform was added, and the tube was shaken vigorously by hand for 15 s. The sample was again incubated at room temperature for 2 min and centrifuged at 12,000g for 15 min at 4 °C. The upper aqueous phase was pipetted into a new tube, 0.5 ml of isopropanol was added, and the mixture was incubated at room temperature for 10 min. The tube was centrifuged at 12,000g for 10 min at 4 °C. The supernatant was removed and the RNA pellet was washed with 1 ml of 75% ethanol. The sample was vortexed and centrifuged at 7,500g for 5 min at room temperature. The pellet was air-dried for 15 min and resuspended in 40 μ l RNase-free water at 60 °C. RNA was DNase-digested using the manufacturer's protocol (Promega). DNase was inactivated via phenol-chloroform extraction. Purified RNA was quantified using a NanoDrop (Wilmington, DE), and first-strand cDNA was synthesized using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Negative controls did not contain reverse transcriptase. Transcripts were amplified using standard PCR conditions (95 °C for 120 s, 95 °C for 20 s, 60 °C for 20 s, 72 °C for 20 s, 34 cycles, 7 °C for 300 s, 4 °C until storage at − 20 °C). Amplified products were run on 2% agarose gels, imaged, and quantified using ImageJ software. AChR primer sequences were as follows (forward primer first, reverse primer second, in 5′ -3′ orientation), CHRNA1: GTCCAATAACGCCGCTGAGG, CTAGCGATGGCTATGGCTGG; CHRNA2: GACTCTTCGGTGAAGGAAGATTG, AGAGCAGAAGA TGGTTGTCCAG; CHRNA3: GCCAAAGAGATTCAAGATGATTGG, TCTGGGGCTATTGAGAAAGTGC; CHRNA4: GACTTCTCGGTGAAG 
